New hope for gallbladder cancer: chemo plus immunotherapy combo tested
NCT ID NCT06591650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a mix of three chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy drug (durvalumab) in people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and how safe it is. About 33 adults who have not had prior treatment for this cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GALLBLADDER ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heated chemo wash during surgery aims to stop gallbladder cancer spread
- New hope for bile duct cancer: targeted chemo combo shows promise in early trial
- New drug combo offers hope for advanced gallbladder cancer patients
- New strategy: removing tumors one by one after chemo for stomach and pancreatic cancers
- Genetic cheat code may unlock safer, stronger chemo cocktail for tough cancers